Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Decitabine for MRD Clearance in AML
NCT03021395Phase 2Withdrawn
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Feb 2017
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of decitabine in acute myeloid leukemia (AML), sponsored by Institute of Hematology and Blood Diseases Hospital. Planned start Feb 2017; status: withdrawn.
02
Drugs
decitabine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT03021395.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03021395.